<DOC>
	<DOC>NCT00056875</DOC>
	<brief_summary>This is a single arm dose escalation study of recombinant human keratinocyte growth factor given to patients undergoing allogeneic bone marrow transplantation who are at high risk for graft versus host disease (GVHD).</brief_summary>
	<brief_title>Recombinant Human Keratinocyte Growth Factor in Unrelated and Related Transplants</brief_title>
	<detailed_description>Completion date provided represents the completion date of the grant per OOPD records</detailed_description>
	<mesh_term>Graft vs Host Disease</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Eligible for full intensity bone marrow transplant (BMT) conditioning but who lack a 6/6 HLA idential sibling donor</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2006</verification_date>
	<keyword>graft versus host disease</keyword>
	<keyword>bone marrow transplant</keyword>
	<keyword>alternative donor</keyword>
</DOC>